Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on May 9, 2023. The filing announces the release of earnings results for the first quarter ended April 1, 2023. The company's ordinary shares and various notes are registered on the New York Stock Exchange.
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the provided text. The filing notes that the company reports both GAAP and non-GAAP financial measures.
Material Changes and Adjustments
The filing outlines the specific adjustments made to derive non-GAAP financial measures for the three months ended April 1, 2023, compared to the prior period ended April 2, 2022. These adjustments include:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Restructuring charges and other termination benefits.
- Unusual litigation costs.
- (Gain) loss on divestitures and investment securities.
- Non-GAAP tax adjustments.
- Foreign currency translation movements.
Notably, the prior year period (ended April 2, 2022) also included adjustments for impairment charges, which are not listed as an adjustment for the current period.
Guidance, Outlook, and Management Commentary
Management utilizes non-GAAP measures to evaluate ongoing operating trends, facilitate comparability between periods, and assess future prospects. These measures exclude items that management believes obscure underlying business operational trends. The filing states that management uses these adjusted measures for planning, forecasting, and determining compensation. No specific forward-looking guidance or numerical outlook is provided within this 8-K text.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific GAAP and non-GAAP revenue, net income, and earnings per share figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the impact of excluded items like amortization and restructuring.
- Assess the impact of foreign currency translation on reported sales growth versus constant currency growth.
- Confirm the status of any unusual litigation or impairment charges mentioned in the full earnings release.